Cue Biopharma, Inc.CUE

時価総額
$7716.1万
PER
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
Net loss-38,980,313-36,698,957-44,784,921-44,161,175-53,010,382
Depreciation and amortization-810,78211922,216
Stock-based compensation7710129
Amortization of operating lease right-of-use asset---3883,839
Amortization of Debt Discount (Premium)--83,694-4,581-320,612
Gain on right-of-use asset modification----276,633
Loss on disposal of fixed asset-3,315-54,274-21,550-3,962
Amortization of Debt Issuance Costs----30,810
Accretion of final payment of term loan----108,696
Account receivable-754,898662,5842-3,085,275
Prepaid expenses and other current assets701,939-487,182381,13250,434-33,602
Other assets--123,4374,971-250,000-
Deposits--1,559,704--148,515-394,721
Accounts payable376,147-1,152,688741,265520,39883,110
Accrued expenses636,975439,290559,8592-1,070,580
Research and development contract liability, current portion5928,588503,263-7,973,255-645,344
Operating lease liability--4,277,54453-735,068
Net cash used in operating activities-26,410,968-30,796,910-32,494,034-38,837,166-41,805,954
Purchases of property and equipment246,353595,259913,039170,746
Cash received from sale of fixed asset-127,500-21,5506,205
Redemption of marketable securities-21,000,000-18,500,000-15,000,000-10,000,000-5,000,000
Purchases of marketable securities4015--29
Net cash provided by investing activities-20,354,246349-24,609,877
Proceeds From At Time Market Offering Net Of Commission And Fees----17
Proceeds from Issuance of Common Stock--571723
Proceeds from Debt, Net of Issuance Costs----5
Proceeds from Issuance of Debt----10
Proceeds from Stock Options Exercised12,500223-
Payment of debt issuance costs----141,749
Restricted stock awards withheld at vesting to cover taxes-91,027271,051750,183199,873
Net cash provided by financing activities451591954
Net decrease in cash, cash equivalents, and restricted cash-42,583,3652331-10,495,333-12,756,698
Purchases of property and equipment in accounts payable or accrued expenses--446,372--57,312
Cash paid for interest----570,347
Right-of-use asset and lease liability (new lease)----11
Operating lease modification--688